Hydroxypropyl Beta-Cyclodextrin Purification for Chronic CNS Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hydroxypropyl beta-cyclodextrin compositions used for treating Niemann-Pick disease contain impurities like propylene glycol, beta-cyclodextrin molecules with no hydroxypropyl substitutions, and bacterial endotoxin, making them unsuitable for chronic intrathecal or intracerebroventricular administration, and their complex mixtures lack precise compositional control, necessitating the development of higher purity and defined pharmaceutical compositions.
Innovation Solution
Development of a pharmaceutical composition comprising beta-cyclodextrin molecules with controlled hydroxypropyl substitution, reduced impurities, and specific ratios, suitable for intrathecal or intracerebroventricular administration, achieved through purification methods such as absorption chromatography on alumina and solvent precipitation, ensuring low levels of propylene glycol and endotoxin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hydroxypropyl beta-cyclodextrin compositions are used for treating Niemann-Pick disease, then therapeutic benefit is achieved, but impurities like propylene glycol, beta-cyclodextrin molecules with no hydroxypropyl substitutions, and bacterial endotoxin make them unsuitable for chronic intrathecal or intracerebroventricular administration
Solution Approach 1:
The patent applies extraction by removing harmful impurities from the hydroxypropyl beta-cyclodextrin composition through purification processes. Specifically, beta-cyclodextrin molecules with no hydroxypropyl substitutions are separated and removed from the mixture, along with other impurities like propylene glycol and bacterial endotoxin, thereby making the composition suitable for chronic intrathecal or intracerebroventricular administration
Solution Approach 2:
The patent applies parameter changes by modifying the compositional parameters of the hydroxypropyl beta-cyclodextrin mixture. The composition is defined with specific parameters: average degree of substitution of at least 2.0, less than 10% beta-cyclodextrin molecules with no hydroxypropyl substitutions, and controlled levels of other impurities. These parameter specifications transform the composition from an impure form to a purified pharmaceutical grade suitable for chronic administration
2Manufacturing precision
If complex mixtures of hydroxypropyl beta-cyclodextrin are used, then therapeutic effect is achieved, but lack of precise compositional control necessitates development of higher purity and defined pharmaceutical compositions
Solution Approach 1:
The patent applies parameter changes by establishing precise compositional parameters for the hydroxypropyl beta-cyclodextrin pharmaceutical composition. The composition is defined with specific measurable parameters including average degree of substitution (at least 2.0), percentage of beta-cyclodextrin molecules with no hydroxypropyl substitutions (less than 10%), and controlled impurity levels. These parameter specifications provide precise compositional control while maintaining therapeutic efficacy
Solution Approach 2:
The patent applies local quality by ensuring uniform distribution and consistent properties throughout the pharmaceutical composition. The purification process ensures that all molecules in the composition meet the specified criteria (average degree of substitution ≥2.0, less than 10% with no substitutions), creating a homogeneous product with predictable and reliable therapeutic performance
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The purified composition provides therapeutic benefit in Niemann-Pick disease by modulating relevant biomarkers and clinical symptoms, with improved safety and stability for chronic use.
Implementation Method 1
purification methods such as absorption chromatography on alumina
Implementation Method 2
purification methods such as absorption chromatography on alumina and solvent precipitation
Data Source
AI summary
This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.